MAP3K8 and breast carcinoma: In this study, we observed that the TPL2 overexpression rate was significantly higher in DCIS (23/30, 76.7%) and IDC (52/80, 65%) groups than that in the Normal group (11/30, 36.7%), which indicated that TPL2 was not only overexpressed in IDC but also in DCIS, suggesting that TPL2 plays a role in promoting the development of breast cancer.